Abstract 5399: Anti-cancer activity of a new LIM-Kinases inhibitor: “LIM-Pyr1”
Authors: Chloé Prunier, Julien Vollaire, Véronique Josserand, Anoek Zomer, Amandine Hurbin, Renaud Prudent, Pascale Cohen, Jacco van Rheenen, Jean-Luc Coll, Marc Billaud, Laurence Lafanechère
Journal: Cancer Research (2015)

Abstract Breast cancer is the second cause of death in Europe with an incidence of 464.00 new cases in 2012. Chemotherapy is frequently used to treat severe breast cancer. Current drugs like taxanes and anthracycline used alone or in combination are efficient. Moreover the use of biomarkers, like HER2 and BRCA status is now helping in the choice of the most adapted chemotherapy to the patient. De novo or acquired resistance limits, however, the clinical usefulness of drugs used in current chemotherapy. The development of new therapeutics effective against drug-resistant cancers thus still represents an important challenge. Our team has discovered a new LIM Kinases (LIMK1/2) inhibitor, “LIM-Pyr1”. LIMK1/2 are situated at a crossroads of several signaling pathways mainly activated by tyrosine kinase receptors and regulate both actin and microtubules dynamics. LIMK1/2 regulate actin dynamics through cofilin phosphorylation. Cofilin is an actin-depolymerizing factor and its phosphorylation inactivates its actin severing activity. LIMK1/2 also regulate microtubule dynamics through a mechanism unknown yet. LIMK1/2 inhibition induce microtubules stabilization (1). Moreover, LIMK1/2 are overexpressed in many invasive cancers and appear to be a relevant target for anticancer therapy (2, 3). We have shown that LIM-Pyr1 is toxic on cell lines resistant to conventional chemotherapy (4) and tested LIM-Pyr1 therapeutic activity on different breast cancer models (xenografts in mice). We found that LIM-Pyr1 shows a potent antitumor activity both on primary and secondary tumors, with no detectable undesirable side effects. The antitumor effect is effective on paclitaxel resistant xenografts. Finally, intravital microscopy analysis indicates that a LIM-Pyr1 treatment induces a strong morphological change of tumor cells inside the tumors and reduces their migration. LIM-Pyr1 and its derivatives could thus represent a pharmacological alternative to overcome resistances often observed when tumors are treated with microtubule targeting agents. (1) O. Bernard, LIM Kinases, regulators of actin dynamics, Int. Journals of Biochemistry and cell biology (2007) 1071-1076 (2) F. Manetti, Recent finding confirm LIM Domain Kinases as emerging target candidates for cancer therapy, Curr. Cancer Drug Targets (2012) 12,543-560 (3) W. Wang, R. Eddy, J. Condeelis, The cofilin pathway in breast cancer invasion and metastasis, Nat. Cancer Reviews (2007) (4) R. Prudent, E. Vassal-Stermann, C-H Nguyen et al., Pharmacological inhibition of LIM Kinases stabilizes microtubules, Cancer Research (2012) Citation Format: Chloé Prunier, Julien Vollaire, Véronique Josserand, Anoek Zomer, Amandine Hurbin, Renaud Prudent, Pascale Cohen, Jacco van Rheenen, Jean-Luc Coll, Marc Billaud, Laurence Lafanechère. Anti-cancer activity of a new LIM-Kinases inhibitor: “LIM-Pyr1”. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 5399. doi:10.1158/1538-7445.AM2015-5399